Overexpression of periostin and distinct mesothelin forms predict malignant progression in a rat cholangiocarcinoma model

Miguel Á. Manzanares, Deanna J.W. Campbell, Gabrielle T. Maldonado, Alphonse E. Sirica – 18 December 2017 – Periostin and mesothelin have each been suggested to be predictors of poor survival for patients with intrahepatic cholangiocarcinoma, although the clinical prognostic value of both of these biomarkers remains uncertain. The aim of the current study was to investigate these biomarkers for their potential to act as tumor progression factors when assessed in orthotopic tumor and three‐dimensional culture models of rat cholangiocarcinoma progression.

Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis

Ahmad Hassan Ali, James H. Tabibian, Navine Nasser‐Ghodsi, Ryan J. Lennon, Thomas DeLeon, Mitesh J. Borad, Moira Hilscher, Marina G. Silveira, Elizabeth J. Carey, Keith D. Lindor – 15 December 2017 – Primary sclerosing cholangitis (PSC) is a risk factor for cholangiocarcinoma (CCA) and gallbladder carcinoma (GBCa). Surveillance for GBCa is recommended, but the clinical utility of surveillance for other hepatobiliary cancers (HBCa) in PSC, namely CCA and hepatocellular carcinoma (HCC), remains unclear.

Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis

Zobair M. Younossi, Rohit Loomba, Quentin M. Anstee, Mary E. Rinella, Elisabetta Bugianesi, Giulio Marchesini, Brent A. Neuschwander‐Tetri, Lawrence Serfaty, Francesco Negro, Stephen H. Caldwell, Vlad Ratziu, Kathleen E. Corey, Scott L. Friedman, Manal F. Abdelmalek, Stephen A. Harrison, Arun J. Sanyal, Joel E. Lavine, Philippe Mathurin, Michael R. Charlton, Zachary D. Goodman, Naga P. Chalasani, Kris V.

Transplanting hepatitis C virus–positive livers into hepatitis C virus–negative patients with preemptive antiviral treatment: A modeling study

Jagpreet Chhatwal, Sumeyye Samur, Emily D. Bethea, Turgay Ayer, Fasiha Kanwal, Chin Hur, Mark S. Roberts, Norah Terrault, Raymond T. Chung – 9 December 2017 – Under current guidelines, hepatitis C virus (HCV)‐positive livers are not transplanted into HCV‐negative recipients because of adverse posttransplant outcomes associated with allograft HCV infection.

Subscribe to